Clinical trials: Neurodegenerative Disorders
Parkinson Disease, Cognitive Impairment
Low Frequency Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson's Disease
Prospective trial of low frequency deep brain stimulation of the ventral subthalamic nucleus to improve cognitive performance in patients with advanced Parkinson's disease.
- Trial name
- NCT03204526
- Testing
- deep brain stimulation
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of California, Davis
Alzheimer's Disease (AD)
Trial of Oxaloacetate in Alzheimer's Disease (TOAD)
The purpose of this study is to determine if oxaloacetate (OAA) is safe and tolerable at doses of up to 2 grams per day in people with Alzheimer's disease (AD).
- Trial name
- TOAD (NCT02593318)
- Testing
- Oxaloacetate (OAA) 1g, Oxaloacetate (OAA) 2g
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Russell Swerdlow
Huntington Disease
Safety and Efficacy of Fenofibrate as a Treatment for Huntington's Disease
The purpose of this research study is to study the safety and efficacy of fenofibrate, an FDA-approved drug for high cholesterol and/or elevated triglycerides (fats), as a treatment for Huntington's disease (HD).
- Trial name
- NCT03515213
- Testing
- Fenofibrate
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, Irvine
Tourette Syndrome
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
This is a Phase 2b, randomized, double-blind, placebo-controlled, dose-optimization study to evaluate the efficacy, safety, and tolerability of NBI-98854 titrated to the subject's optimal dose administered once daily (qd) for a…
- Trial name
- NCT03325010
- Testing
- Valbenazine
- Where
- 35 sites in United States, Puerto Rico
- Volunteers
- 127 people
- Sponsor
- Neurocrine Biosciences
Amyotrophic Lateral Sclerosis
The Effect of RNS60 on ALS Biomarkers
Amyotrophic Lateral Sclerosis (ALS) is a rare lethal neurodegenerative disease involving inflammation. Riluzole, the only drug for ALS, improves median survival by 3 months. This prompts new treatments of ALS.
- Trial name
- RNS60 (NCT03456882)
- Testing
- RNS60
- Where
- 23 sites in United States, Italy
- Volunteers
- 147 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Muscular Atrophy, Spinal
Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy
Open-label, multi-center clinical study is to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamics (PD), and efficacy of Risdiplam (RO7034067) in infants with Type 1 spinal muscular atrophy (SMA).
- Trial name
- FIREFISH (NCT02913482)
- Testing
- Risdiplam
- Where
- 32 sites in United States, Belgium and 14 more
- Volunteers
- 62 people
- Sponsor
- Hoffmann-La Roche
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder
The objective of this study is to evaluate the safety and efficacy of eculizumab in pediatric participants (aged 2 to < 18 years) with relapsing neuromyelitis optica spectrum disorder (NMOSD).
- Trial name
- NCT04155424
- Testing
- Eculizumab
- Where
- 35 sites in United States, Canada and 5 more
- Volunteers
- 5 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Amyotrophic Lateral Sclerosis
Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)
The purpose of this research study is to evaluate the safety and effectiveness of CK-2017357 when taken with or without riluzole (also called Rilutek®) in patients with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT01709149
- Testing
- CK-2017357, Riluzole
- Where
- 75 sites in United States, Canada and 6 more
- Volunteers
- 711 people
- Sponsor
- Cytokinetics
Motor OFF Episodes Associated With Parkinson's Disease
A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes) Compared to an Approved Drug Used to Treat People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)
A study of an investigational drug to see how it affects the people with Parkinson's Disease complicated by motor fluctuations ("OFF" Episodes) compared to an approved drug used to treat people with Parkinson's Disease…
- Trial name
- NCT03391882
- Testing
- APL-130277, subcutaneous apomorphine
- Where
- 31 sites in Austria, France and 4 more
- Volunteers
- 113 people
- Sponsor
- Sumitomo Pharma America, Inc.
Parkinson Disease
Effectiveness and Implementation of the HiBalance Program in Clinical Practice
This effectiveness-implementation study is a part of the larger study BETA-PD (Balance, Elderly, Training and Activity in Parkinson's Disease), which has the long-term goal to reduce the risk of falling in people with Parkinson's…
- Trial name
- BETA-PD (NCT02727478)
- Testing
- HiBalance training program
- Where
- Sweden
- Volunteers
- 117 people
- Sponsor
- Karolinska Institutet
Alzheimer's Disease
A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia
The main purpose of this study is to evaluate the safety and the effect on brain tau of the study drug LY3202626 in participants with mild Alzheimer's disease (AD) dementia.
- Trial name
- NAVIGATE-AD (NCT02791191)
- Testing
- LY3202626
- Where
- 76 sites in United States, Australia and 2 more
- Volunteers
- 316 people
- Sponsor
- Eli Lilly and Company
Insomnia
SIESTA: Sleep Intervention to Enhance Cognitive Status and Reduce Beta Amyloid
The objective of this study is to compare the efficacy of a sleep intervention on improving cognitive function in older adults with symptoms of insomnia, determine the association between change in sleep measures and change in…
- Trial name
- NCT03954210
- Testing
- Cognitive Behavioral Therapy for Insomnia (CBT-I), Sleep and Lifestyle Education
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Mild Cognitive Impairment, Alzheimer Disease
Safety and Immunogenicity of Repeated Doses of ABvac40 in Patients With a-MCI or Vm-AD
Alzheimer's disease (AD) is the most common type of dementia, accounting for 50-75% of the estimated 47 million people with dementia worldwide.
- Trial name
- NCT03461276
- Testing
- ABvac40
- Where
- 23 sites in France, Italy and 2 more
- Volunteers
- 134 people
- Sponsor
- Araclon Biotech S.L.
Myotonic Dystrophy 1, Excessive Daytime Sleepiness
Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1
The primary objective of this study is to evaluate the safety and efficacy of pitolisant compared with placebo in treating excessive daytime sleepiness (EDS) in patients with Myotonic Dystrophy Type 1 ages 18 to 65 years.
- Trial name
- NCT04886518
- Testing
- Pitolisant Oral Tablet
- Where
- 13 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Harmony Biosciences Management, Inc.
Parkinson Disease
Clinical Evaluation of the Infinity Deep Brain Stimulation System
The purpose of this post-market study is to characterize the clinical performance of the Infinity Deep Brain Stimulation (DBS) system, including the Implantable Pulse Generator (IPG), directional DBS leads, extensions, iPad…
- Trial name
- PROGRESS (NCT02989610)
- Testing
- Omnidirectional stimulation, Directional stimulation
- Where
- 41 sites in United States, Australia and 6 more
- Volunteers
- 234 people
- Sponsor
- Abbott Medical Devices
Parkinson Disease
Walking and mHealth to Increase Participation in Parkinson Disease
Identifying effective ways to improve function, slow decline and reduce disability is a high priority for people living with Parkinson disease and other chronic conditions.
- Trial name
- WHIPPD (NCT03517371)
- Testing
- mHealth delivered exercise program, Exercise only
- Where
- 2 sites in United States
- Volunteers
- 140 people
- Sponsor
- Boston University Charles River Campus
Parkinson Disease, Brain Stimulation
Cerebellar Transcranial Direct Current Stimulation in Parkinson's Disease
Parkinson's disease (PD) is the second most common neurodegenerative disorder and affects approximately 1 million people in the United States with total annual costs approaching 11 billion dollars.
- Conditions
- Parkinson Disease, Brain Stimulation, Cerebellum
- Trial name
- NCT04046055
- Testing
- Transcranial direct current stimulation at 2 mA, Transcranial direct current stimulation at 4 mA
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Thorsten Rudroff
Parkinson Disease, Parkinsons Disease With Dementia
Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease
Parkinson's disease (PD) is the second most common neurodegenerative disorder causing motor and non-motor symptoms. PD is characterized by death of dopaminergic (DA) neurons in the substantia nigra (SN) pars compacta and…
- Trial name
- PD Nilotinib (NCT02954978)
- Testing
- Nilotinib 150mg oral capsule [Tasigna], Nilotinib 300mg oral capsule [Tasigna]
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Georgetown University
Spinal Muscular Atrophy Type II, Spinal Muscular Atrophy Type III
Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Types II or III
The purpose of this study is to identify the maximum tolerated dosage of sodium phenylbutyrate in children with spinal muscular atrophy types II or III; and to determine if the drug has an effect on SMN mRNA and protein levels.
- Trial name
- NPTUNE01 (NCT00439569)
- Testing
- sodium phenylbutyrate
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- Westat
Dystonia-Parkinsonism, Adult-Onset, Parkinson Disease
Unlocking Dystonia From Parkinson's Disease With Directional DBS Technology
This study occurs during five visits that are already scheduled as part of "Biomarkers to Guide Directional DBS for Parkinson's Disease" (ClinicalTrials.gov Identifier: NCT03353688).
- Trial name
- NCT03409120
- Testing
- Boston Scientific Vercise PC IPG with directional DBS lead
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Alabama at Birmingham